10286- ML-16 RMPV REMISSION INDUCTION/MAINTENANCE THERAPY FOR ELDERLY PATIENTS WITH CENTRAL NERVOUS SYSTEM LYMPHOMA
Takuro Ehara, Mitsuaki Shirahata, Tomonari Suzuki, Syunsaku Takayanagi, Kazuhiko Mishima · 2024
Read 10286- ML-16 RMPV REMISSION INDUCTION/MAINTENANCE THERAPY FOR ELDERLY PATIENTS WITH CENTRAL NERVOUS SYSTEM LYMPHOMA by Takuro Ehara, Mitsuaki Shirahata, Tomonari Suzuki, Syunsaku Takayanagi, Kazuhiko Mishima (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11605646.txt.
Description
Takuro Ehara and four co-authors report results for a drug regimen in elderly patients with brain lymphoma. Their 2024 report covers a four-drug mix called RMPV, given without whole-brain radiation. Patients were sixty-five or older and treated at one center over seven years. The plan induced remission first, then maintained it for two years.
Forty-three patients took part, most with primary brain lymphoma. Median survival reached about fifty-one months, with about nineteen and a half months before progression. Nearly three quarters reached complete response. Daily function and mental scores improved after remission. Side effects like rash, kidney strain, and nerve damage forced dose cuts in some, guiding careful use.
Catalog record
| CREATOR | Takuro Ehara, Mitsuaki Shirahata, Tomonari Suzuki, Syunsaku Takayanagi, Kazuhiko Mishima |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |